RenovoRx Eyes Q2 2026 Earnings Amid Pancreatic Cancer Trial Milestones
Event summary
- RenovoRx to report Q2 2026 earnings on August 12, highlighting RenovoCath commercial adoption
- $563K in RenovoCath sales in Q1 2026, up from $1.1M annual sales in 2025
- Phase III TIGeR-PaC trial for pancreatic cancer nearing full enrollment
- FDA Orphan Drug Designation secured for oxaliplatin in pancreatic cancer
The big picture
RenovoRx's Q2 earnings call comes as it accelerates commercialization of its RenovoCath device, while advancing a pivotal trial for pancreatic cancer. The company is positioning itself in a competitive oncology space where targeted drug delivery and regulatory milestones could drive valuation shifts. Its ability to scale revenues and secure additional FDA designations will be critical in maintaining investor confidence.
What we're watching
- Commercial Momentum
- Whether RenovoRx can sustain its revenue growth trajectory with expanded adoption at high-volume cancer centers.
- Regulatory Pathway
- The pace at which the Phase III TIGeR-PaC trial delivers final data in mid-to-late 2027 and its potential impact on FDA approval timelines.
- Pipeline Expansion
- How RenovoRx leverages its Orphan Drug Designation and investigator-initiated trials to broaden the clinical utility of its TAMP platform across multiple oncology indications.
Related topics